논문 상세보기
pp.101-106
혼합 간세포-담관암종은 조직학적 특성이 다양한 원발성 간암의 드문 형태이다. 혼합 간세포-담관암종의 근치적 치료 법은 수술적 절제가 유일하나, 진행성 혼합 간세포-담관암종의 치료에 대해서는 잘 정립되어 있지 않다. 저자들은 진행성 혼합 간세포-담관암종에서 선행항암화학요법을 시행 후 근치적 수술이 가능하였고, 수술 15개월 후까지 재발을 보이지 않은 증례를 보고하는 바이다.
Combined hepatocellular-cholangiocarcinoma (HCC-CC) is a primary liver cancer with histopathologic features of both hepatocelluar carcinoma and cholangiocarcinoma. As combined HCC-CC has been associated with poor outcomes, accurate diagnosis and proper treatment planning for patients are considered to be important for improving survival. Currently, surgery is known as the only treatment modality offering potential cure for localized disease. However, there are little published treatment options for advanced or recurrent disease. Furthermore, no published reports exist in respect to the applying successful curative resection after neoadjuvant therapy for advanced combined HCC-CC. Here, we report a case of combined HCC-CC subtype with stem cell feature, intermediate type who underwent curative surgical resection after neoadjuvant chemotherapy consisting of cisplatin and gemcitabine. Pathologic report revealed negative resection margin and followup imaging study shows no evidence of tumor recurrence.
